OPK OPKO HEALTH, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 944809 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-8.3%
TTM net income YoY17.9%
TTM EPS YoY24.0%
Revenue 3-yr CAGR-16.7%
Net income 3-yr CAGR—
Margins
Gross margin46.2%
Operating margin-25.5%
Net margin-29.5%
FCF margin-27.0%
EBITDA margin-8.3%
Returns
ROE-12.2%
ROA-7.6%
ROIC (approx.)-12.4%
Asset turnover0.26x
Leverage & solvency
Liabilities / assets40.6%
Debt / equity0.00x
Current ratio4.97x
Interest coverage2.08x
Cash quality & payout
Operating cash flow / net income0.84x
Accruals ratio-1.2%
Payout ratio—
Capex / revenue2.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $606.88M | $713.14M | $863.50M | $1.00B | $1.77B |
| Cost of revenue | $400.94M | $494.63M | $545.37M | $715.98M | — |
| Gross profit | $205.94M | $218.51M | $318.13M | $288.22M | — |
| R&D expense | $124.03M | $105.21M | $89.59M | $73.89M | $76.85M |
| SG&A expense | $223.00M | $304.22M | $300.56M | $372.67M | $468.86M |
| Operating income | -$117.41M | -$152.06M | -$157.02M | -$226.25M | $18.75M |
| Interest expense | $0 | $47.47M | $13.51M | $12.06M | $18.88M |
| Pretax income | -$241.36M | -$10.36M | -$184.32M | -$391.52M | -$14.03M |
| Income tax | -$15.71M | $42.84M | $4.44M | -$63.50M | $15.49M |
| Net income | -$225.68M | -$53.22M | -$188.86M | -$328.40M | -$30.14M |
| EBITDA | -$25.78M | -$53.89M | -$51.72M | -$117.60M | $97.47M |
| EPS (basic) | -0.30 | -0.08 | -0.25 | -0.46 | -0.05 |
| EPS (diluted) | -0.30 | -0.08 | -0.25 | -0.46 | -0.05 |
| Weighted avg. shares (diluted) | 751.13M | 694.02M | 751.77M | 719.06M | 648.08M |
| Balance sheet | |||||
| Cash & equivalents | $364.41M | $426.58M | $95.88M | $153.19M | $134.71M |
| Receivables | $90.25M | $118.02M | $123.38M | $127.31M | $259.64M |
| Inventory | $52.73M | $56.80M | $65.70M | $74.06M | $86.50M |
| Current assets | $581.88M | $662.09M | $309.48M | $394.52M | $823.01M |
| PP&E, net | $72.81M | $70.13M | $75.43M | $82.88M | $79.73M |
| Goodwill | $320.85M | $529.25M | $598.26M | $595.85M | $520.60M |
| Intangibles | $446.43M | $616.61M | $740.28M | $823.52M | $321.68M |
| Total assets | $1.93B | $2.20B | $2.01B | $2.17B | $2.40B |
| Current liabilities | $146.68M | $193.10M | $200.05M | $213.48M | $330.01M |
| Short-term debt | $1.74M | $437.20M | $1.99M | $1.72M | — |
| Long-term debt | $2.26M | $3.00M | $50,600 | $9.29M | $205.27M |
| Total debt | $4.00M | $440.20M | $2.04M | $11.01M | $205.27M |
| Total liabilities | $663.98M | $834.76M | $622.48M | $605.61M | $714.59M |
| Shareholders' equity | $1.27B | $1.37B | $1.39B | $1.56B | $1.69B |
| Net debt | -$360.41M | $13.62M | -$93.84M | -$142.18M | $70.56M |
| Cash flow statement | |||||
| Operating cash flow | -$178.54M | -$183.49M | -$28.20M | -$95.19M | $38.34M |
| Capital expenditure | $12.28M | $25.01M | $16.27M | $24.58M | $32.16M |
| Free cash flow | -$190.82M | -$208.50M | -$44.47M | -$119.77M | $6.18M |
| Investing cash flow | $230.30M | $352.21M | -$18.20M | $91.04M | $35.95M |
| Financing cash flow | -$118.06M | $184.17M | -$11.30M | $22.97M | -$10.35M |
| Depreciation & amortization | $91.63M | $98.18M | $105.30M | $108.66M | $78.72M |
| Stock-based compensation | $10.71M | $11.05M | $11.41M | $18.51M | $13.63M |
| Share buybacks | $47.04M | $90.22M | $0 | $0 | — |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.